Principal Consultant, MIDD Platform Science Lead
Pharmetheus AB, Sweden
Martin Bergstrand is a Principal Consultant and MIDD platform science lead at Pharmetheus. He holds a PhD in Pharmacometrics from Uppsala University and has twenty years of drug development experience in areas such as metabolic disorders, autoimmune diseases, infectious diseases, oncology, and haematological disorders.
In 2012, Martin co-founded the consulting company Pharmetheus AB. Since then, he has engaged as a strategic advisor for multiple clients and served as the main responsible consultant for over 50 pharmacometric data analysis projects on behalf of more than 20 different clients. These projects have ranged from pre-clinical translational projects to submission-ready large-scale phase III PKPD analyses, contributing to over 5 successful NDA filings.
Martin has first-hand experience with pharmacometric analysis of a wide variety of endpoints, including time-to-event analysis, Markov models, mechanism-based models for multiple linked endpoints, and the characterization of complex pharmacokinetics. He has authored more than 40 peer-reviewed articles and has a special interest in the development of methods for efficient communication regarding MIDD.
